LIXTE Biotechnology Secures $1.05 Million Through New Offering
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT and LIXTW), a leading clinical-stage pharmaceutical organization, is excited to share the successful arrangement of a registered direct offering valued at $1.05 million. This offering, which involves the sale of 434,784 shares of common stock at a price of $2.415 each, positions LIXTE to enhance its capital resources while adhering to Nasdaq’s at-the-market regulations.
Details of the Offering
Alongside this stock issuance, LIXTE is set to conduct a concurrent private placement that will offer unregistered warrants for purchasing an additional 434,784 shares. Each warrant will have an exercise price of $2.29, allowing holders to exercise these options for the next five years from their issuance date.
Financing Goals
The anticipated revenue from this transaction will significantly aid LIXTE's working capital and support various corporate initiatives. The Company is committed to advancing its cancer drug development pipeline, which includes innovative therapies that hold promise for patients.
The Role of H.C. Wainwright & Co.
LIXTE Biotechnology has engaged H.C. Wainwright & Co. as the sole placement agent for this offering, ensuring a strategic approach to maximize the capital raised. This collaboration aims to facilitate a smooth and effective issuance process while complying with all regulatory standards.
Significant Financial Impact
The total gross proceeds expected from this offering will be roughly $1.05 million before any costs incurred by the placement agent and other related expenses. This capital will play a crucial role in bolstering LIXTE's ongoing and future clinical trials and initiatives.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is on a mission to redefine cancer treatment through innovative drug development. At the center of their therapeutic advancements is LB-100, a proprietary compound demonstrated to be safe and effective in clinical settings. This first-in-class PP2A inhibitor has shown potential to enhance treatment outcomes across various chemotherapy and immunotherapy regimens. LIXTE’s unique approach to tumor treatment focuses on a new paradigm in cancer biology.
Pioneering Cancer Therapy Development
The Company is actively advancing the clinical trials for LB-100, which operates within a new therapeutic model, aiming to significantly improve patient survival rates. With no existing competition in this treatment space, LIXTE is poised to make substantial contributions to cancer biology.
Investor Relations and Further Information
The Company strives to keep its investors informed and engaged as it progresses in its development initiatives. For further details, inquiries can be directed to LIXTE’s investor relations team via email or through their general information number. This commitment to transparent communication allows stakeholders to remain abreast of LIXTE's strategic movements and clinical advancements.
Contact Information
To learn more or engage with LIXTE, interested parties can reach out by email or phone. General inquiries can be directed at (631) 830-7092, while investors are encouraged to contact the dedicated line at (888) 289-5533.
Frequently Asked Questions
What is the total amount raised from the offering?
LIXTE Biotechnology has announced a total of $1.05 million raised from the offering.
What is the purpose of the funds raised in this offering?
The funds will be used for working capital and other general corporate purposes, particularly to support drug development efforts.
Who is managing the offering?
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
What is the exercise price of the issued warrants?
The warrants have an exercise price of $2.29 per share.
How long will the warrants be exercisable?
The warrants will be exercisable for a period of five years from the date of issuance.
